Expert insights. Personalized for you.
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program. MORE
The post CVS Ignores DEA, Says It’s Already Selling CBD Products appeared first on Leafly. Industry Politics cannabidiol cbd DEA FDAThe nation's largest drugstore chain is selling CBD products in 8 states. Meanwhile, independent CBD stores are being raided by police in Texas. MORE
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MORE
As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received. MORE
According to the Daily, the testing delay comes after farmers and states alike complained there wouldn’t be enough DEA labs to handle demand. DEA will still expect states to work with their laboratories to try to achieve certification for the 2021 crop year,” he added. MORE
The U.S. Food and Drug Administration and the Drug Enforcement Administration seized forty-four websites offering to sell illicit vaping cartridges containing tetrahydrocannabinol (THC), the primary psychoactive component of the cannabis plant. MORE
Well that came out of the blue in the midst of all the other dire news racing through the sector. Cannabis Business Times reports Effective … Read More. Breaking News MORE
The Drug Enforcement Administration (DEA) finalized its plans to authorize the cultivation of 3,200,000 grams of marijuana for research purposes next year—a 30 percent increase from 2019’s quota. DEA Finalizes Plan To Grow 3.2 MORE
Circuit Court of Appeals that the DEA’s refusal to reschedule cannabis damaged their health and that the federal agency should remove cannabis from Schedule 1. Federal appeals court to DEA: Reconsider marijuana’s Schedule 1 status. MORE
A federal court dismissed a lawsuit against the Drug Enforcement Administration (DEA) on Friday after determining that the agency had fulfilled a requirement to process applications for research-grade marijuana manufacturers. Marijuana Moment reports. MORE
Defendants are acting-Attorney General Matthew Whitaker, the acting director of the DEA and the federal government. Additional Resources: Appeal Hearing in Cannabis Lawsuit Against the DEA , Dec. A federal lawsuit against the U.S. Drug Enforcement Administration and the U.S. MORE
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications. MORE
As a Marine Corps federal prosecutor, DEA Drug Task Force Commander and state narcotics prosecutor, Charles spent many years engaged in the War on Drugs. A Former DEA Prosecutor’s Journey into the Global Cannabis Industry. MORE
The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. Prescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. Health Politics cannabidiol cbd Epidiolex GW Pharma GW Pharmaceuticals MORE
DEA Announces Steps Necessary to Improve Access to Marijuana Research. The DEA is providing notice of pending applications from entities applying to be registered to manufacture marijuana for researchers. Following. The Press Release in full. Department of Justice. MORE
After a significant outcry by the hemp community, the USDA is backing down from its requirement that all hemp be tested at DEA-registered labs for the 2020 season. BY ALICIA ALTENAU, GREEN LIGHT LAW GROUP —. MORE
WASHINGTON – DEA Acting Administrator Uttam Dhillon today announced the publication of the 2019 National Drug Threat Assessment, which outlines the threats posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs. Press Release. MORE
The Marijuana Time introduce their article by writing… A cannabis researcher at Arizona’s Scottsdale Research Institute plans to sue the Drug Enforcement Administration (DEA) over what she is saying is low-grade cannabis that is unacceptable for testing. MORE
” To date, however, the agency has neither affirmed or denied any of the 26 applicants that have sought the DEA’s permission for a federal cultivation license. “[This filing is] asking the court for an order compelling the DEA to process our application. MORE
The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action. MORE
The Drug Enforcement Administration continues to support additional research into marijuana and its components, and we believe registering more growers will advance the scientific and medical research already being conducted,” said DEA Acting Administrator Dhillon. “DEA MORE
The report reveals … ndustry members worry the limitation could delay THC testing and create bottlenecks, especially in remote areas far from a DEA-registered lab. “It This is a departure for the DEA, which does not require labs to be accredited to handle narcotics. MORE
The DEA’s announcement lowers physician barriers to prescribing Epidiolex because they won’t have to notify the agency when prescribing it. The expansion comes two years after the DEA first took Epidiolex off the most-restrictive class of controlled substances. That decision, issued months after the FDA approved the drug for treating certain types of epilepsy, was the first time the DEA removed any type of cannabis from Schedule 1. MORE
The DEA’s announcement signals the “beginning of the end” of federal marijuana prohibition, as the policy change allows federal agencies to evaluate and assess the medical use and abuse potential of marijuana with (limited) political interference. BY EMILY BURNS, GREEN LIGHT LAW GROUP —. MORE
On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. The post The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval? MORE
The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA. Like a child who does not want to clean his or her room, the DEA simply refuses to take any major action, despite the whirlwind of reforms surrounding them on a daily basis. The court’s sense of urgency finally puts judicial pressure on the DEA. The DEA is now forced to face the issue. MORE
Two days before a federal court deadline, the DEA says it will do what it said it would do three years ago. The post DEA Says It Will Finally Let Others Grow Research-Grade Cannabis appeared first on Leafly. Politics DEA research MORE
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. Here, DEA can act with little expenditure of resources.”. MORE
The DEA now estimates that, under the new rules, it may approve between three and 15 total applicants. In 2016, the DEA publicly announced that it would, for the first time, begin accepting applications from private entities wishing to grow research-grade cannabis. MORE
Cannabis research in the USA has been held back by the DEA’s stance on the issue, although it has been increasing the amount of cannabis it wants produced for research over the last couple of years. The DEA says the proposed rule will see additional registered growers and more diverse variety of marijuana strains available for research. Currently, the DEA has 37 pending applications to grow marijuana for research. MORE
You might think it’s California,but actually it is …… According to recently published DEA data about illegal grows it is Kentucky, where both recreational and medical marijuana are still illegal. The DEA confiscated over 1.8 MORE
DEA will still expect states to work with their laboratories to try to achieve certification for the 2021 crop year,” he added. “We USDA drops DEA hemp testing requirement for 2020, while FDA acknowledges demand for CBD. Hemp Industry Daily report. MORE
According to figures published in the DEA’s Domestic Cannabis Eradication/Suppression Statistical Report, the agency and its law enforcement partners confiscated an estimated 2.82 LAW ENFORCEMENT assets DEA eradication legalization seizures MORE
Drug Enforcement Administration (DEA) when it comes to DEA’s handling of petitions to remove marijuana from the list of most dangerous drugs. The DEA has routinely denied each petition, or declined to accept it outright. MORE
Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. This likely would have been longer, but the DEA had not anticipated a legal threat to force some action. MORE
The post Wasn’t the DEA Going to Let Others Grow Research-Grade Cannabis? Science & Tech DEA nida researchYes, it was. So why has the agency delayed applications? Sue Sisley demands an answer, and the courts agree with her. MORE
DEA Related Topics NORML
APRIL 8, 2020
As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received.
NORML
JULY 16, 2019
According to figures published in the DEA’s Domestic Cannabis Eradication/Suppression Statistical Report, the agency and its law enforcement partners confiscated an estimated 2.82 LAW ENFORCEMENT assets DEA eradication legalization seizures
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
MARCH 26, 2020
The DEA now estimates that, under the new rules, it may approve between three and 15 total applicants. In 2016, the DEA publicly announced that it would, for the first time, begin accepting applications from private entities wishing to grow research-grade cannabis.
NORML
SEPTEMBER 20, 2019
We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program.
NORML
AUGUST 26, 2019
The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.
NORML
OCTOBER 21, 2019
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
|
Leafly
AUGUST 26, 2019
Two days before a federal court deadline, the DEA says it will do what it said it would do three years ago. The post DEA Says It Will Finally Let Others Grow Research-Grade Cannabis appeared first on Leafly. Politics DEA research
NORML
AUGUST 2, 2019
” To date, however, the agency has neither affirmed or denied any of the 26 applicants that have sought the DEA’s permission for a federal cultivation license. “[This filing is] asking the court for an order compelling the DEA to process our application.
Leafly
AUGUST 19, 2019
The post Wasn’t the DEA Going to Let Others Grow Research-Grade Cannabis? Science & Tech DEA nida researchYes, it was. So why has the agency delayed applications? Sue Sisley demands an answer, and the courts agree with her.
Leafly
APRIL 6, 2020
The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. Prescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. Health Politics cannabidiol cbd Epidiolex GW Pharma GW Pharmaceuticals
Leafly
MARCH 22, 2019
The post CVS Ignores DEA, Says It’s Already Selling CBD Products appeared first on Leafly. Industry Politics cannabidiol cbd DEA FDAThe nation's largest drugstore chain is selling CBD products in 8 states. Meanwhile, independent CBD stores are being raided by police in Texas.
|
|
WeedAdvisor
JULY 4, 2019
Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. Here, DEA can act with little expenditure of resources.”.
Cannabis Law Report
MARCH 24, 2020
Cannabis research in the USA has been held back by the DEA’s stance on the issue, although it has been increasing the amount of cannabis it wants produced for research over the last couple of years. The DEA says the proposed rule will see additional registered growers and more diverse variety of marijuana strains available for research. Currently, the DEA has 37 pending applications to grow marijuana for research.
WeedAdvisor
AUGUST 28, 2019
Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. This likely would have been longer, but the DEA had not anticipated a legal threat to force some action.
Cannabis Law Report
JANUARY 31, 2020
WASHINGTON – DEA Acting Administrator Uttam Dhillon today announced the publication of the 2019 National Drug Threat Assessment, which outlines the threats posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs. Press Release.
Cannabis Law Report
FEBRUARY 28, 2020
After a significant outcry by the hemp community, the USDA is backing down from its requirement that all hemp be tested at DEA-registered labs for the 2020 season. BY ALICIA ALTENAU, GREEN LIGHT LAW GROUP —.
Cannabis Law Report
MARCH 21, 2020
The Drug Enforcement Administration continues to support additional research into marijuana and its components, and we believe registering more growers will advance the scientific and medical research already being conducted,” said DEA Acting Administrator Dhillon. “DEA
CannaTech
JUNE 23, 2019
As a Marine Corps federal prosecutor, DEA Drug Task Force Commander and state narcotics prosecutor, Charles spent many years engaged in the War on Drugs. A Former DEA Prosecutor’s Journey into the Global Cannabis Industry.
Cannabis Law Report
DECEMBER 2, 2019
The Drug Enforcement Administration (DEA) finalized its plans to authorize the cultivation of 3,200,000 grams of marijuana for research purposes next year—a 30 percent increase from 2019’s quota. DEA Finalizes Plan To Grow 3.2
Canna Law Blog
JUNE 1, 2019
Drug Enforcement Administration (DEA) when it comes to DEA’s handling of petitions to remove marijuana from the list of most dangerous drugs. The DEA has routinely denied each petition, or declined to accept it outright.
SMPL
APRIL 8, 2020
The DEA’s announcement lowers physician barriers to prescribing Epidiolex because they won’t have to notify the agency when prescribing it. The expansion comes two years after the DEA first took Epidiolex off the most-restrictive class of controlled substances. That decision, issued months after the FDA approved the drug for treating certain types of epilepsy, was the first time the DEA removed any type of cannabis from Schedule 1.
Cannabis Law Report
AUGUST 24, 2019
The Marijuana Time introduce their article by writing… A cannabis researcher at Arizona’s Scottsdale Research Institute plans to sue the Drug Enforcement Administration (DEA) over what she is saying is low-grade cannabis that is unacceptable for testing.
Cannabis Law Report
SEPTEMBER 9, 2019
The DEA’s announcement signals the “beginning of the end” of federal marijuana prohibition, as the policy change allows federal agencies to evaluate and assess the medical use and abuse potential of marijuana with (limited) political interference. BY EMILY BURNS, GREEN LIGHT LAW GROUP —.
WeedAdvisor
JUNE 1, 2019
The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA. Like a child who does not want to clean his or her room, the DEA simply refuses to take any major action, despite the whirlwind of reforms surrounding them on a daily basis. The court’s sense of urgency finally puts judicial pressure on the DEA. The DEA is now forced to face the issue.
Cannabis Law Report
FEBRUARY 27, 2020
DEA will still expect states to work with their laboratories to try to achieve certification for the 2021 crop year,” he added. “We USDA drops DEA hemp testing requirement for 2020, while FDA acknowledges demand for CBD. Hemp Industry Daily report.
Cannabis Law Report
AUGUST 26, 2019
DEA Announces Steps Necessary to Improve Access to Marijuana Research. The DEA is providing notice of pending applications from entities applying to be registered to manufacture marijuana for researchers. Following. The Press Release in full. Department of Justice.
Cannabis Law Report
NOVEMBER 20, 2019
The report reveals … ndustry members worry the limitation could delay THC testing and create bottlenecks, especially in remote areas far from a DEA-registered lab. “It This is a departure for the DEA, which does not require labs to be accredited to handle narcotics.
Cannabis Law Report
DECEMBER 23, 2019
The U.S. Food and Drug Administration and the Drug Enforcement Administration seized forty-four websites offering to sell illicit vaping cartridges containing tetrahydrocannabinol (THC), the primary psychoactive component of the cannabis plant.
Cannabis Law Report
JUNE 3, 2019
Circuit Court of Appeals that the DEA’s refusal to reschedule cannabis damaged their health and that the federal agency should remove cannabis from Schedule 1. Federal appeals court to DEA: Reconsider marijuana’s Schedule 1 status.
Cannabis Law Report
NOVEMBER 11, 2019
You might think it’s California,but actually it is …… According to recently published DEA data about illegal grows it is Kentucky, where both recreational and medical marijuana are still illegal. The DEA confiscated over 1.8
Freedom Leaf
OCTOBER 15, 2018
On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. The post The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?
Cannabis Law Report
NOVEMBER 22, 2019
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada.
Marijuana Lawyer Blog
JANUARY 12, 2019
Defendants are acting-Attorney General Matthew Whitaker, the acting director of the DEA and the federal government. Additional Resources: Appeal Hearing in Cannabis Lawsuit Against the DEA , Dec. A federal lawsuit against the U.S. Drug Enforcement Administration and the U.S.
The Joint Blog
MARCH 3, 2020
According to the Daily, the testing delay comes after farmers and states alike complained there wouldn’t be enough DEA labs to handle demand. DEA will still expect states to work with their laboratories to try to achieve certification for the 2021 crop year,” he added.
Cannabis Law Report
OCTOBER 21, 2019
A federal court dismissed a lawsuit against the Drug Enforcement Administration (DEA) on Friday after determining that the agency had fulfilled a requirement to process applications for research-grade marijuana manufacturers. Marijuana Moment reports.
277 
Let's personalize your content